1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

$Thumbnail for Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND$

IBCL - 740

Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Antibiotic Escalation and Early Infectious Complications Following Antithymocyte Globulin (ATG) and Posttransplant Cyclophosphamide (PTCy)-Based Haploidentical Stem Cell Transplantation

CT - 1003

Antibiotic Escalation and Early Infectious Complications Following Antithymocyte Globulin (ATG) and Posttransplant Cyclophosphamide (PTCy)-Based Haploidentical Stem Cell Transplantation

Sally Chahine

Poster Presenter: Sally Chahine

SOHO 2026 Annual Meeting

Posters by Title

Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Antibiotic Escalation and Early Infectious Complications Following Antithymocyte Globulin (ATG) and Posttransplant Cyclophosphamide (PTCy)-Based Haploidentical Stem Cell Transplantation

Anticoagulation Safety and Thromboembolic Outcomes in Patients With Chronic Lymphocytic Leukemia and Atrial Fibrillation Receiving BTK Inhibitors: A Propensity-Matched TriNetX Analysis

Antifungal Prophylaxis in Acute Promyelocytic Leukemia: The Azole Dilemma During Arsenic Trioxide Therapy

Antigen Escape in Relapsed/Refractory Large B-Cell Lymphoma: A Case Series of CD20 Expression Loss After CD20-Directed Therapy

Application of CRISPR-Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with P53 Gene Mutations

Arlocabtagene Autoleucel in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Final Analysis From the Phase 1 Study

Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1-3 Prior Regimens

Arterial and Venous Thrombosis in Myeloproliferative Neoplasm Hospitalizations: Distinct Associations With Mortality and Resource Utilization